The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer

OBJECTIVE: CAR-T/NK cells have had limited success in the treatment of solid tumors, such as colorectal cancer (CRC), in part because of the heterogeneous nature of tumor-associated antigens that lead to antigen-negative relapse after the initial response. This barrier might be overcome by enhancing...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaohui, Qiu, Wei, Liu, Haoyu, He, Min, He, Wei, Li, Zhan, Wu, Zhiqiang, Xu, Xiang, Chen, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546094/
https://www.ncbi.nlm.nih.gov/pubmed/37731205
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546094/
https://www.ncbi.nlm.nih.gov/pubmed/37731205
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0033

Ejemplares similares